Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
26 studies found for:    alpharadin | Open Studies
Show Display Options
Rank Status Study
1 Recruiting BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Condition: Non Small Cell Lung Cancer With Bone Metastatses
Intervention: Biological: Xofigo
2 Recruiting Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY 88-8223)
3 Not yet recruiting Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone
Conditions: Prostate Carcinoma Metastatic to the Bone;   Stage IV Prostate Adenocarcinoma;   Hormone-refractory Prostate Cancer
Interventions: Drug: Niraparib;   Radiation: Radium Ra 223 Dichloride
4 Recruiting Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Condition: Castrate-Resistant Prostate Cancer
Interventions: Drug: Atezolizumab;   Drug: Radium-223 dichloride
5 Recruiting Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Other: Background hormonal therapy
6 Recruiting Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Conditions: Prostate Cancer;   Bone Metastases;   Prostate Neoplasms
Interventions: Drug: LHRH agonist/antagonist;   Drug: Bicalutamide;   Radiation: Radium-223 dichloride
7 Recruiting Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Drug: Exemestane;   Drug: Everolimus
8 Recruiting Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo;   Drug: Bortezomib;   Drug: Dexamethasone
9 Recruiting Radium-223 Dichloride Long-term Follow-up Program
Condition: Neoplasm Metastasis / Bone and Bones
Intervention: Other: Data Collection
10 Recruiting Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Radium Ra 223 dichloride with Enzalutamide;   Drug: Enzalutamide
11 Recruiting Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)
Condition: Prostate Carcinoma
Interventions: Drug: Radium-223 dichloride;   Other: Conventional or high dose radiotherapy
12 Recruiting Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
Condition: Castration-Resistant Prostatic Cancer
Intervention: Drug: Radium-223 dichloride, (Xofigo, BAY88-8223)
13 Recruiting NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Prostate Carcinoma
Interventions: Procedure: Contrast-enhanced Magnetic Resonance Imaging;   Drug: Fludeoxyglucose F-18;   Drug: Fluorine F 18 Sodium Fluoride;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography
14 Recruiting Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: Radium-223-dichloride (Xofigo, BAY88-8223)
15 Not yet recruiting Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: Xofigo (Radium-223 dichloride, BAY88-8223
16 Recruiting uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Conditions: Prostate Cancer Metastatic;   Bone Metastases
Interventions: Drug: Injection of PET tracer 68Ga-NOTA-AE105;   Device: PET/CT
17 Recruiting Phase II Trial of Ra-223 Dichloride and Hormonal Treatment
Condition: Breast Cancer
Interventions: Drug: Ra-223 dichloride;   Drug: Denosumab;   Drug: Hormone Therapy
18 Recruiting Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Radiation: Radium 223
19 Not yet recruiting Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
Condition: Prostate Cancer
Intervention: Drug: radium-223 dichloride
20 Recruiting PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in CRPC Treated With Radium-223
Conditions: Prostate Cancer;   Castration Resistant;   Radium 223
Intervention: Drug: Radium 223

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.